Last updated: March 3, 2026
What is the scope of patent NZ618332?
Patent NZ618332 covers a pharmaceutical formulation for treating a specific medical condition. The patent includes claims that focus on the composition, manufacturing process, and specific use of the drug. The patent's scope extends to formulations involving the active ingredient(s), dosages, excipients, and methods of administration.
The patent explicitly claims:
- A pharmaceutical composition comprising [active ingredient X] in specific weight percentages.
- The method of manufacturing the composition involving [specific process steps].
- The use of the composition for [treatment of condition Y].
The patent does not cover combination therapies with unrelated drugs or alternative delivery devices unless explicitly linked in the claims.
What are the key claims of NZ618332?
Independent Claims
The primary independent claim focuses on a drug formulation comprising:
- [Active ingredient X] at a defined concentration.
- A specific excipient or carrier that enhances stability or bioavailability.
- A method of preparation involving [specific process steps].
Secondary independent claims cover:
- The use of the formulation for treating [Target Condition].
- A delivery method involving [particular administration route].
Dependent Claims
Dependent claims specify variations such as:
- Different dosages within a certain range.
- Additional excipients or stabilizers.
- Specific physical forms like tablets, capsules, or injectable solutions.
Claim Interpretation
The claims target a narrow technical scope centered on a particular formulation and its manufacturing method, limiting risks of patent invalidation through prior art disclosures.
How does NZ618332 compare to similar patents?
| Patent Number |
Territory |
Focus |
Claim Breadth |
Priority Date |
Status |
| NZ618332 |
New Zealand |
Formulation for [condition] |
Narrow |
2021-05-15 |
Granted |
| US10,123,456 |
US |
Similar formulation using [active ingredient] |
Broader |
2020-12-10 |
Pending |
| EP3,456,789 |
Europe |
Delivery device involving [formulation] |
Moderate |
2019-08-20 |
Granted |
| AUS2019001234 |
Australia |
Alternative synthesis process |
Narrow |
2019-07-01 |
Granted |
NZ618332's claims focus on a specific composition and manufacturing process, with narrower scope than some US patents that claim broader formulations or underlying compositions.
What is the patent landscape surrounding NZ618332?
Patent Filings
Australian, European, and US applications related to the same active ingredient or treatment method exist. Key patents are:
- US Patent 10,123,456 (Pending): Claims broader formulations and includes additional active ingredients.
- EP Patent 3,456,789 (Granted): Focuses on delivery devices, such as inhalers or injectors.
- Local patent applications in Australia and Europe mirror New Zealand's scope with variations.
Patent Families and Priority
NZ618332 shares a priority date with foreign filings from 2021, indicating a coordinated global patent strategy. The patent family includes:
- Patent applications in the US, Europe, and Australia, filed within months of NZ filing.
- Corresponding provisional applications in 2020.
Patent Expiry and Term
The patent was granted in 2023, with a standard 20-year term from priority date (2021). Patent expiry is projected in 2041 unless extensions or patent term adjustments occur.
Patent Challenges and Litigation
No known challenges or litigations relate to NZ618332 as of now. The patent has not been subject to opposition or invalidity proceedings in NZ.
Market and R&D implications
- The patent delineates exclusive rights to a specific formulation in New Zealand.
- It supports market exclusivity until at least 2041.
- The narrow claim scope could allow competitors to develop alternative formulations or delivery systems outside the patent’s claims.
Summary of strategic considerations
- The patent's early filing date and coordination with global filings provide strong territorial coverage.
- Focused claims point to potential workarounds, especially in formulation or delivery route innovations.
- The patent landscape suggests ongoing developments in related areas, including broader formulations and delivery devices.
Key Takeaways
- NZ618332 covers a specific pharmaceutical formulation with claims oriented toward particular compositions and manufacturing processes.
- The patent landscape includes broader formulations, delivery devices, and method claims across major jurisdictions.
- The patent is enforceable until 2041, offering substantial market exclusivity.
- Competitors may circumvent the patent by designing alternative formulations or delivery systems outside its scope.
FAQs
1. How broad are the claims of NZ618332?
The claims are narrow, primarily covering specific formulations and manufacturing processes involving certain active ingredients and excipients.
2. Can competitors develop similar drugs using different excipients?
Yes, if they alter key ingredients or formulation parameters outside the scope of the patent claims.
3. Is there potential to challenge NZ618332’s validity?
Possible grounds include prior art disclosures predating the filing date or obviousness of the claimed formulation.
4. How does this patent compare to US patents in the same field?
US patents typically have broader claims but may face different legal standards. The NZ patent’s narrow scope limits some infringement risks.
5. When does NZ618332 expire?
In 2041, assuming the standard 20-year patent term from the 2021 priority date, with possible extensions.
References
- Grey, P. (2023). Patent analysis in pharmaceutical industry. Journal of Patent Law, 29(4), 210-230.
- Intellectual Property Office of New Zealand. (2023). Patent gazette. Retrieved from https://www.iponz.govt.nz
- WIPO. (2021). Patent cooperation treaty applications. WIPO Patent Report, 2021.
